Impact BioMedical, Inc. (IBO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Impact BioMedical, Inc. (IBO) has a cash flow conversion efficiency ratio of 0.225x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.99 Million) by net assets ($-8.85 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Impact BioMedical, Inc. for the company's overall valuation and market capitalisation.
Impact BioMedical, Inc. - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Impact BioMedical, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Impact BioMedical, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Impact BioMedical, Inc. ranked by their cash flow conversion efficiency. Explore Impact BioMedical, Inc. (IBO) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ni Hsin Resources Bhd
KLSE:7215
|
-0.012x |
|
Century Synthetic Fiber Corp
VN:STK
|
-0.064x |
|
Uniflex Technology Inc
TW:3321
|
0.050x |
|
Laserbond Ltd
AU:LBL
|
0.102x |
|
ICD Co. Ltd
KQ:040910
|
0.093x |
|
Retail Food Group Ltd
AU:RFG
|
0.000x |
|
Rama Phosphates Limited
NSE:RAMAPHO
|
0.011x |
|
Cofix Group Ltd
TA:CFX
|
0.532x |
Annual Cash Flow Conversion Efficiency for Impact BioMedical, Inc. (2017–2024)
The table below shows the annual cash flow conversion efficiency of Impact BioMedical, Inc. from 2017 to 2024. View Impact BioMedical, Inc. (IBO) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $7.24 Million | $-5.64 Million | -0.779x | -671.98% |
| 2023-12-31 | $28.26 Million | $-2.85 Million | -0.101x | +23.95% |
| 2022-12-31 | $32.67 Million | $-4.33 Million | -0.133x | +87.98% |
| 2021-12-31 | $2.94 Million | $-3.25 Million | -1.104x | -610.22% |
| 2020-12-31 | $-5.28K | $-1.14K | 0.216x | +116.83% |
| 2019-12-31 | $94.89K | $-121.98K | -1.286x | -251.97% |
| 2018-12-31 | $197.12K | $-71.99K | -0.365x | +66.34% |
| 2017-12-31 | $295.22K | $-320.34K | -1.085x | -- |
About Impact BioMedical, Inc.
Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application … Read more